Article Text

Download PDFPDF
A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies
  1. M Dastmalchi1,
  2. C Grundtman1,
  3. H Alexanderson2,
  4. C P Mavragani3,
  5. H Einarsdottir5,
  6. S Barbasso Helmers1,
  7. K Elvin4,
  8. M K Crow3,
  9. I Nennesmo6,
  10. I E Lundberg1
  1. 1
    Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden
  2. 2
    Department of Physical Therapy and Rheumatology Unit, Department of Medicine, Karolinska University Hospital Solna, Stockholm, Sweden
  3. 3
    Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, USA
  4. 4
    Department of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital Solna, Stockholm, Sweden
  5. 5
    Department of Radiology, Karolinska University Hospital Solna, Stockholm, Sweden
  6. 6
    Division of Pathology, Karolinska University Hospital Huddinge, Stockholm, Sweden
  1. M Dastmalchi, Rheumatology, Unit, Karolinska University Hospital, Solna, SE-171 76 Stockholm, Sweden; maryam.dastmalchi{at}


Objective: To investigate the effect of the tumour necrosis factor (TNF) blocking agent infliximab in patients with treatment-resistant inflammatory myopathies.

Methods: A total of 13 patients with refractory polymyositis (PM), dermatomyositis (DM), or inclusion body myositis (IBM) were treated with 4 infliximab infusions (5 mg/kg body weight) over 14 weeks. Outcome measures included myositis disease activity score with improvement defined according to The International Myositis Assessment and Clinical Studies Group (IMACS), and MRI. Repeated muscles biopsies were investigated for cellular infiltrates, major histocompatibility complex (MHC) class I and II, TNF, interleukin (IL)1α, IL6, high mobility group box chromosomal protein 1 (HMGB-1), interferon γ (IFNγ), myxovirus resistance protein A (MxA) and membrane attack complex (MAC) expression. Type I IFN activity was analysed in sera.

Results: Nine patients completed the study. Three patients discontinued due to adverse events and one due to a discovered malignancy. Three of the completers improved by ⩾20% in three or more variables of the disease activity core set, four were unchanged and two worsened ⩾30%. No patient improved in muscle strength by manual muscle test. At baseline, two completers had signs of muscle inflammation by MRI, and five at follow-up. T lymphocytes, macrophages, cytokine expression and MAC deposition in muscle biopsies were still evident after treatment. Type I IFN activity was increased after treatment.

Conclusions: Infliximab treatment was not effective in refractory inflammatory myopathies. In view of radiological and clinical worsening, and activation of the type I IFN system in several cases, infliximab is not an alternative treatment in patients with treatment-resistant myositis.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Competing interests: IEL: the study was supported by an unrestricted grant from Schering-Plough, Nordic Biotech. The other authors declare that they have no competing interests.

  • Funding: This study was supported by an unrestricted grant from Schering-Plough, Nordic Biotech and from The Swedish Research Council K2005-74X-14045-05AK, The Swedish Rheumatism Association, King Gustaf V 80-year Foundation, Professor Nanna Svartz Foundation, Karolinska Institutet Foundation and Börje Dahlin Foundation.

  • Ethics approval: The trial was approved by the local ethics committee at Karolinska University Hospital and all patients signed a written informed consent prior to their participation in the study.